# DEBOXA for Inoperable NET Liver Metastases

> **NCT03881306** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Xiangya Hospital of Central South University** · enrollment: 60 (estimated)

## Conditions studied

- Neuroendocrine Tumors
- Neoplasm Metastasis
- Liver

## Interventions

- **DRUG:** D-TACE

## Key facts

- **NCT ID:** NCT03881306
- **Lead sponsor:** Xiangya Hospital of Central South University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-01
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2020-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03881306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03881306, "DEBOXA for Inoperable NET Liver Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03881306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*